Share Twitter LinkedIn Facebook Email Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel therapeutic interventions.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read